Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in

Status Terminated

Clinical Trial Summary

WATERFALL is an investigator-initiated international multicenter open-label randomized clinical trial comparing aggressive versus moderate fluid resuscitation in acute pancreatitis. The main outcome variable will be the proportion of patients with moderate-to-severe AP. Aggressive fluid resuscitation will consist in Lactated Ringer Solution (LR) 20 ml/kg bolus (administered over 2 hours) followed by LR 3 ml/kg/h and moderate a LR bolus 10 ml/kg in case of hypovolemia or no bolus in patients with normal volemia, followed by LR 1.5 ml/kg/h. The patients will be assessed at 3 (±1), 12 (±4), 24 (±4), 48 (±4) and 72 (±4) hours from recruitment, and fluid resuscitation will be adjusted to the patient´s clinical and analytical status according to a protocol. Subgroup analysis will include patients with systemic inflammatory response syndrome (SIRS) at admission, with persistent (>48h) SIRS and with hypovolemia at admission. Based on available data (Sternby et al, Ann Surg 2019) we expect a 35% incidence of moderate to severe AP in the moderate arm. Sample sizes of 372 per arm of treatment (744 patients) achieve 80% power to detect a difference of 10% between the treatment arms at a significance level (alpha) of 0.05 using a two-sided z-testNA, assuming a 10% dropout. These results assume that 3 sequential tests are made using the O'Brien-Fleming spending function to determine the test boundaries. All analyses will be performed on an intention-to-treat basis. The trial could be stop early for efficacy (primary end-point) if the observed two-sided P value is <0.0002 at the first interim analysis (after 1/3 of patients have been enrolled) or is <0.012 at second interim analysis (after 2/3 of patients have been enrolled), favoring aggressive fluid resuscitation. At final analysis, the hypothesis that the incidence of moderate-to-severe pancreatitis is similar in the two treatment arms will be rejected if p<0.046

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04381169
Study type	Interventional
Source	Hospital General Universitario de Alicante
Contact
Status	Terminated
Phase	Phase 3
Start date	May 28, 2020
Completion date	September 25, 2021

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05410795` - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting	`NCT04195347` - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase	Phase 1/Phase 2
Completed	`NCT04735055` - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed	`NCT02928718` - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated	`NCT02885441` - Treatment of Acute Pancreatitis With Ketorolac	Phase 4
Completed	`NCT02563080` - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting	`NCT01626911` - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis	N/A
Completed	`NCT01507766` - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis	Phase 4
Completed	`NCT04901949` - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting	`NCT04814693` - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis	N/A
Completed	`NCT02743364` - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis	Phase 2
Recruiting	`NCT05281458` - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections	N/A
Not yet recruiting	`NCT04990336` - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis	N/A
Not yet recruiting	`NCT03259880` - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals	N/A
Completed	`NCT02543658` - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension	Phase 2
Recruiting	`NCT06023771` - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting	`NCT05501314` - Remote Home Monitoring Acute Pancreatitis	N/A
Completed	`NCT02897206` - Imipenem Prophylaxis in Patients With Acute Pancreatitis	Phase 4
Recruiting	`NCT03634787` - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting	`NCT04989166` - Effect of Nano-curcumin Supplementation in Acute Pancreatitis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis — WATERFALL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms